To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
USA117th CongressHR-7640| House
| Updated: 5/3/2022
Gus M. Bilirakis
Republican Representative
Florida
Cosponsors (1)
Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
USA117th CongressHR-7640| House
| Updated: 5/3/2022
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Gus M. Bilirakis
Republican Representative
Florida
Cosponsors (1)
Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted